New study paves way for faster FSHD drug development
NCT ID NCT04038138
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 28 times
Summary
This study aims to speed up the development of new drugs for facioscapulohumeral muscular dystrophy (FSHD), a muscle-weakening disease. Researchers will test new ways to measure muscle function and disease progression in 100 adults over 24 months. The goal is to create reliable tools that future drug trials can use to see if treatments are working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Lille
Lille, Hauts-de-France, 59000, France
-
CHU de Nice
Nice, Provence-Alpes-Côte d'Azur Region, 06000, France
-
Myology institute Association
Paris, Île-de-France Region, 75013, France
Conditions
Explore the condition pages connected to this study.